CN102285962B - Phenoxy alkyl piperazine compounds, preparation method thereof and medicinal use thereof - Google Patents
Phenoxy alkyl piperazine compounds, preparation method thereof and medicinal use thereof Download PDFInfo
- Publication number
- CN102285962B CN102285962B CN 201110170726 CN201110170726A CN102285962B CN 102285962 B CN102285962 B CN 102285962B CN 201110170726 CN201110170726 CN 201110170726 CN 201110170726 A CN201110170726 A CN 201110170726A CN 102285962 B CN102285962 B CN 102285962B
- Authority
- CN
- China
- Prior art keywords
- preparation
- piperazine
- compound
- productive rate
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BGFICFHXSNQDNK-XSFVSMFZSA-N C/N=C/c(cc1)ccc1OCCN1CCN(CC(Nc2ncc[s]2)=O)CC1 Chemical compound C/N=C/c(cc1)ccc1OCCN1CCN(CC(Nc2ncc[s]2)=O)CC1 BGFICFHXSNQDNK-XSFVSMFZSA-N 0.000 description 1
- NIJFUZXPXGSSOE-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1OCCN1CCN(CC(Nc2ncc[s]2)=O)CC1 Chemical compound CC(C)(C)c(cc1)ccc1OCCN1CCN(CC(Nc2ncc[s]2)=O)CC1 NIJFUZXPXGSSOE-UHFFFAOYSA-N 0.000 description 1
- WKTNCQGUZAOFTA-UHFFFAOYSA-N Cc(cccc1)c1OCCN(CC1)CCN1C(c1ccc[s]1)=O Chemical compound Cc(cccc1)c1OCCN(CC1)CCN1C(c1ccc[s]1)=O WKTNCQGUZAOFTA-UHFFFAOYSA-N 0.000 description 1
- CCCAQMDUQBAPCN-UHFFFAOYSA-N Cc1cc(OCCN(CC2)CCN2C(c(cc2)ccc2Cl)=O)c(C)c(C)c1 Chemical compound Cc1cc(OCCN(CC2)CCN2C(c(cc2)ccc2Cl)=O)c(C)c(C)c1 CCCAQMDUQBAPCN-UHFFFAOYSA-N 0.000 description 1
Images
Abstract
The invention relates to the field of medical chemistry and particularly relates to phenoxy alkyl piperazine compounds (I) or (II), a preparation method thereof, a medicinal preparation containing the same and medicinal use thereof. Ar, L and R are defined in the description. Pharmacological tests prove that the compounds have certain blocking activity for voltage-gated potassium channels. Therefore, the compounds and the pharmaceutical preparations of the compounds can be used for treating series of diseases caused by dysfunction of potassium channels, such as arrhythmia and hypoxicischemic brain damage.
Description
Technical field
The present invention relates to the pharmaceutical chemistry field, be specifically related to a class benzene oxyalkyl piperazine compounds, its preparation method and comprise its pharmaceutical preparation and medicinal use thereof.
Background technology
Irregular pulse is the major disease of serious threat people ' s health and quality of life, the sales volume of antiarrhythmic drug is year by year ascendant trend, and just increasingly rejuvenation of ill crowd, therefore, the research of antiarrhythmic drug has huge Social benefit and economic benefit.
Antiarrhythmic drug can be divided into four classes according to the mechanism of action difference, at present clinical application is mainly so that III class anti-arrhythmic---potassium channel blocker is as main, comprise amiodarone, P162a, sotalol etc., its electric physiological effect is to prolong myocardial action potential time-histories and effective refractory period.But the drug main of present clinical use will act on the quick composition I of myocardial delayed rectifier potassium channel
Kr, serious proarrhythmia side effect has appearred in clinical use: when heart rate is slow, and I
KrRetarding agent is property out of control to the prolongation of Action Potential Duration, causes torsade de pointes; And heart rate is when accelerating, I
KrRetarding agent weakens the therapeutic action of ventricular arrhythmia.Therefore, the treatment plan of cardiac arrhythmia should only not be confined to the regulation and control disease to the single ionic passage, and should be counted as the synthesis result that the different kinds of ions channel properties changes.On the other hand, mostly traditional antiarrhythmic medicament is for the ventricular arrhythmia that begins to worsen, and has ignored at cardiac arrhythmia in early days to the control of atrial arrhythmia symptom and to deteriorated into the prevention of ventricular arrhythmia by atrial arrhythmia.In valtage-gated type potassium-channel, a class delayed rectification potassium-channel I is arranged
K, have three kinds of hypotypes, be respectively I
Kr, I
Ks, I
Kur, I wherein
KurSelective expression's atrial muscle cell has been confirmed as the target of atrial arrhythmia disease, and I
Kr, I
KsDual retarding agent also be in the news to have and be better than simple I
KrThe preferably anti-arrhythmia effect of retarding agent, therefore, to valtage-gated type Delayed Rectifier Potassium Channels I
Kr, I
Ks, I
KurComprehensive regulation, become the ARR therapeutic strategy of very promising many targets.
Summary of the invention
The link closely development trend of current antiarrhythmic drug of the present invention, design and synthesize out the compound that a class has benzene oxyalkyl piperazine structure, pharmacological testing proves, the compounds of this invention has certain blocking activity for valtage-gated type potassium-channel, this compounds and medicinal preparations thereof can be used for the treatment of a series of diseases that cause owing to the potassium-channel dysfunction, for example, irregular pulse, ischemia injury etc.
Compound general formula of the present invention is as follows:
Wherein Ar represents the aromatic nucleus that replaces; Aromatic nucleus is selected from phenyl ring or contains five yuan or hexa-atomic fragrant heterocycle of 1～2 nitrogen-atoms, sulphur atom or Sauerstoffatom; Replace the single replacement of expression, two replacement or three replacements; Substituting group is selected from hydrogen atom, halogen, amino, hydroxyl, nitro, cyano group, trifluoromethyl, trifluoromethoxy, C
1～C
4Alkyl, C
1～C
4Alkoxyl group, C
1～C
4Amide group, C
1～C
4Carbalkoxy;
L represents-(CH
2)
n-, wherein n is 2～4 integer;
R represents single replacement or polysubstituted, and polysubstituted finger is two to be replaced or three replacements; Substituting group is selected from hydrogen atom, halogen, amino, hydroxyl, nitro, cyano group, trifluoromethyl, trifluoromethoxy, C
1～C
4Alkyl, C
1～C
4Alkoxyl group, C
1～C
4Amide group or C
1～C
4Carbalkoxy.
The present invention also comprises general formula (I) or (II) pharmacy acceptable salt of compound, described salt preferably salt hydrochlorate or hydrobromate.
Wherein Ar preferably represents the thiphene ring, thiazole ring, imidazole ring, pyrrole ring, furan nucleus, oxazole ring, pyridine ring or the phenyl ring that replace, and substituting group is preferably from hydrogen atom, halogen, amino, hydroxyl, nitro, cyano group, trifluoromethyl, trifluoromethoxy, alkyl, alkoxyl group, ester group or amide group.
L preferably represents-CH
2CH
2-,-CH
2CH
2CH
2-or-CH
2CH
2CH
2CH
2-.
The invention also discloses the preparation method of general formula (I) and general formula (II) compound.
The preparation method of general formula (I) compound comprises:
Compound (IV) compound (V) general formula (I)
Wherein X represents halogen, and the definition of Ar, L, R is the same.
Wherein compound IV can prepare with following method:
Compound V can prepare with following method:
Preferred preparation method comprises:
Compound (III) and Piperazine anhydrous reaction are obtained compound (IV), and R base fortified phenol and X-L-X reaction obtain compound (V), and compound (IV) obtains general formula (I) compound with compound (V) reaction.
Preferred 60～100 ℃ of the temperature of reaction that compound (III) and Piperazine anhydrous react, preferred 4～12 hours of reaction times.React the used preferred dehydrated alcohol of solvent or methyl alcohol, the preferred sulfur oxychloride that adds in the reaction solution.
Preferred 100～120 ℃ of the temperature of reaction that R base fortified phenol and X-L-X react in preferred 2～4 hours of reaction times, also should add alkali in the reaction solution, such as potassium hydroxide, sodium hydroxide etc.
Preferred 60～90 ℃ of the temperature of reaction that compound (IV) and compound (V) react, preferred 4～10 hours of reaction times.React the used preferred acetonitrile of solvent, DMF (DMF) or chloroform, also preferably add alkali in the reaction solution, such as triethylamine, salt of wormwood etc.
The preparation method of general formula (II) compound comprises:
Wherein the definition of Ar, L, R is the same.
Wherein compound VI can prepare with following method:
Compound VI I can prepare with following method:
Preferred preparation method comprises:
Compound (V) and Piperazine anhydrous reaction are obtained compound (VI), Ar-NH
2Obtain compound (IV) and compound (VII) with the chloroacetyl chloride reaction, compound (VI) obtains general formula (II) compound with compound (VII) reaction.
Preferred 60～100 ℃ of the temperature of reaction that compound (V) and Piperazine anhydrous react, preferred 6～12 hours of reaction times.React the used preferred dehydrated alcohol of solvent or methyl alcohol, preferred 40% hydrochloric acid or 25% Hydrogen bromide of adding in the reaction solution.
Ar-NH
2Preferred 0～50 ℃ of the temperature of reaction of reacting with chloroacetyl chloride, preferred 1～4 hour of reaction times, the preferred acetonitrile of reaction solvent for use, DMF (DMF) or chloroform, the preferred alkali that adds also in the reaction solution is such as triethylamine, salt of wormwood etc.
Preferred 60～90 ℃ of the temperature of reaction that compound (VI) and compound (VII) react, preferred 4～10 hours of reaction times.React the used preferred acetonitrile of solvent, DMF (DMF) or chloroform, also preferably add alkali in the reaction solution, such as triethylamine, salt of wormwood.
General formula (I) and the described compound of general formula (II) can adopt common separation method to carry out purifying, such as recrystallization, column chromatography etc.
The invention also discloses a kind of pharmaceutical composition, wherein contain compound or its pharmacy acceptable salt and the pharmaceutically acceptable carrier of general formula (I) or general formula (II).Compound of the present invention can add pharmaceutically acceptable carrier and make common medicinal preparations, such as tablet, capsule, pulvis, syrup, liquor, suspension agent, injection, can add the common medicinal supplementary material such as spices, sweeting agent, liquid or solid filler or thinner.
The modes such as that compound of the present invention administering mode clinically can adopt is oral, injection.
The clinical used dosage of compound of the present invention is 0.01mg～1000mg/ days, also can depart from this scope according to the weight of the state of an illness or the difference of formulation.
The invention has the advantages that, described compound has certain blocking activity to valtage-gated type potassium channel, this compounds and medicinal preparations thereof can be used for the treatment of a series of diseases that cause owing to the potassium-channel dysfunction, for example, and the diseases such as irregular pulse, ischemia injury.The characteristics such as in addition, preparation method provided by the invention has the reaction conditions gentleness, and abundant raw material is easy to get, and operation and aftertreatment are simple.
Part pharmacology test and the result of the compounds of this invention are as follows:
One, the compounds of this invention is to valtage-gated type potassium channel I
KurThe retardation of electric current detects
Experimental technique: in view of the Kv1.5 gene I that encodes in vivo
KurPotassium channel, the present invention adopts the HEK cell of transfection Kv1.5 gene, and the full cell patch tongs technology of using artificial, research compound calculate and suppress activity value IC the impact of cell currents
50Value, experimental result sees Table 1.(reference: The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293cells.Biochem Pharmacol 2007,74,1596-607)
Table 1 the compounds of this invention is to I
KurThe blocking activity IC of potassium channel current
50
By as seen from Table 1, compound of the present invention has stronger I
KurThe retardation of potassium channel current, effect are better than positive control drug Archie Li Te.
Illustrate: structure corresponding to the compounds of this invention numbering is the structure among the embodiment identical with this numbering.Such as compound 1, namely this compound is exactly the compound of embodiment 1.
Two, the compounds of this invention is to I
Kr, I
KsThe retardation of potassium channel current detects
Experimental technique: with acute enzymolysis process separating guinea pig myocardial cell, adopt fast activate constituent and slow activate constituent in full cell patch pincers record (model: HEKA, EPC-10) myocardial cell delayed rectification electric current.The compound of selecting representative structure in the embodiment of the invention adds in the perfusate of the electric current of measuring at least 10min after dissolving, the data of collection are carried out data analysis at Pulse-fit software, calculate each compound to I
KrAnd I
KsIC
50Value, experimental result sees Table 2
Experimental implementation:
1. the separation of guinea pig myocardium cell: cavy is hit unconsciously, and speed is cored dirty, puts into 4 ℃ without the calcium tyrode's solution, pruning is placed on the Langendorff device, without calcium tyrode perfusion 5min, with containing 1mg/ml Type II collagenase, 0.1mg/mlProtease 0.5%BSA contains CaCl
2The low calcium Zinciodati Comp solution perfusion heart of 150 μ mol/L becomes soft to heart, and is lax, takes off heart, ventricle shredded place 37 ℃ of temperature of fresh enzyme liquid to incubate, and stirs gently 5-10min, and inclining supernatant liquor, with containing CaCl
2The tyrode's solution dilution of 1mmol/L, this is first part of cell storage liquid; With the method operation, obtain second, third part cell storage liquid.Perfusate passes into 5%CO
2+ 95%O
2Saturated.Cell uses after placing 2h.
2. full cell patch tongs technology: get enchylema to cell pool, treat cell attachment, use the extracellular fluid perfusion, flow velocity 2ml/min, select anti-calcium, band is cell clearly, utilizes Three dimensional steerable device traveling electrode to cell surface, make eletrode tip and cell surface form high resistance seals with negative pressure, further inhale the broken cell film with negative pressure, make liquid and intracellular fluid conducting in the electrode, form full cell state, after carrying out the compensation of electric capacity and series impedance, carry out the voltage clamp record.Signal is amplified by patch clamp amplifier through the guiding of Ag/AgCl electrode, the boost pulse that computer is set by the program granting, and be added on the cell, the electrical signal that cell produces is changed through transmodulator, is stored in the computer.All stimulus signal controls, the current data sampling and analyzing is finished by pulseV8.60.After this was studied all tested materials and all is dissolved in dehydrated alcohol, the dilute with water same concentrations added in the extracellular fluid, and alcohol concn is up to 0.1%, and the preliminary experiment result of this research shows, under this concentration on experimental result without impact.Administration after record current is stablized 10min, the electric current behind the record administration 10min, experiment is carried out at 25～30 ℃.
3. stimulation parameter: I
Kr, I
KsRecord: the wake flow value that records two electric currents.With containing 0.1mmol/L CdCl
2The extracellular fluid perfusion, sustaining voltage-50mV, depolarize is to 60mV, time length 500ms, sustaining voltage is to-50mV, time length 1000ms, record I
KsThen with voltage clamp at-50mV 1000ms, record I
Kr
Table 2 compound is to I
Kr, I
KsThe retardation IC of potassium channel current
50
The result shows, and is selected to having the compound of high, medium and low blocking activity with the Kv1.5 potassium channel current, for guinea pig myocardium I
Kr, I
KsAll have certain blocking activity, near positive drug Archie Li Te, point out this compounds to have polyion channel blocking activity.
Three, the compounds of this invention is on the impact of atrial fibrillation rat model cardiac muscle Cx43 protein expression level
1. modeling method: 30 of male SD rats (250-280g), continuously tail vein injection calcium chloride vagusstoff (CaCl
2-ACh) mixed solution (10mL/Kg, wherein CaCl
210mg/ml, ACh 66 μ g/ml) modeling in 7 days; Rat was divided into model group and administration group on the 4th day at random in modeling.Administration group rat carries out abdominal injection front 5 minutes of modeling in the 4th day by the 2.5mg/Kg dosage.
2. the preparation of protein sample: tested the 8th day, anesthetized rat takes out rapidly heart, places to pass into 95%O
2, 5%CO
20 ℃ of K-H liquid (NaCl:118, KCl:4.7, MgSO of mixed gas
4: 1.2, KH
2PO
4: 1.2, NaHCO
3: 24.8), clean heart, suck dry moisture shreds heart, adds lysate and proteinase inhibitor, and homogenate on ice about half an hour, centrifugal 5 minutes (12000rpm) gets supernatant.
3. the preparation of typical curve: adopt the Bradford method to survey protein concentration, as standard substance production standard curve, record sample concentration with BSA, sample concentration is transferred to 2 μ g/ μ l, sex change 5min, packing ,-80 ℃ of preservations.
4.Western blotting method thought-read flesh Cx43 protein content: sample (protein content 50 μ g) joined in 12% the polyacrylamide gel, electrophoresis, be transferred on the nitrocellulose filter, the sealing of 5% skim-milk, 4 ℃ of night incubation of rabbit polyclonal antibody (dilution in 1: 2000), TBST cleans three times (10min/ time), adds the goat antirabbit (dilution in 1: 5000) of HRP mark, the room temperature shaking table was hatched 90 minutes, and TBST cleans three times (10min/ time).Add the ECL reactant to cellulose membrane, exposure, luminous autography is on the X film.Use Quantity one image analysis software that albumen one band on the film is carried out photodensitometry.Experiment repeats 4 times, is figure with optical density(OD) mean value.
5. experimental result: as shown in Figure 1, intravenous injection 10mL/Kg CaCl
2-ACh mixed solution is made rat atrial fibrillation pathological model, and the horizontal compared with normal group of slit connexin expression (control group) significantly reduces in the rat heart muscle, and prompting rat heart muscle electric signal transmission is unusual.Behind the abdominal injection the compounds of this invention 7, atrial fibrillation rat model cardiac muscle Cx43 protein expression level significantly increases, near normal group.This phenomenon points out this compound may pass through regulation and control myocardial cell's communicating function, to improve the electric signal transmission between the myocardial cell.
Four, anti-atrial arrhythmia effect in the body of the compounds of this invention
1. experimental technique: male SD rat (body weight 270-300g) is divided into model group, administration group and control group at random.Tested the 1st～3 day, with 10% chloral hydrate anesthesia rat (0.3mL/100g), recording ecg after the anesthesia.Tail vein injection CaCl
2-ACh mixed solution (10mg/mL CaCl
2+ 6.6ug/mL Ach mixes, and injected dose is 0.1mL/100g), the record atrial fibrillation time length.The atrial fibrillation time to recover continuous 6 sinus rhythms as atrial fibrillation disappearance mark, is tested the whole process electrocardiogram monitoring with the typical atrial fibrillation electrocardiogram(ECG of the rear appearance of mixed solution injection (the P ripple disappears, and the f ripple occurs) beginning timing.According to the atrial fibrillation time length first three day, the administration group is 10min before the beginning modeling with the animal random packet in the 4th day, the medicine of abdominal injection corresponding dosage, and ditto operation is operated to the 7th day more than the repetition again.The 8th day, rat was put to death, and gets rat left heart atrium, be hung on to be full of in the oxygen-saturated constant temperature KH bath of liquid groove, and preload 1g, 1.5 times of threshold potentials of 1Hz frequency stimulated approximately 1 hour, began to test after stablize sample.By BL-420F biological function system, adopt continuously two stimulus methods to measure myocardium effective refractory period ERP.All experimental example numbers are no less than 6, carry out the group difference statistical test with means standard deviation.
2. experimental result: shown in Fig. 2～4; the compounds of this invention 22 and 7 can effectively resist rat atrial fibrillation effect (Fig. 2; Fig. 3); effect is better than the sotalol with dosage; the atrial muscle cell effective refractory period (ERP) that this compound causes atrial fibrillation shortens significant protective effect (Fig. 4), and ERP numerical value is returned to normal level after the medication.
Five, antiarrhythmia effect in the body of the compounds of this invention
1. experimental technique:
(1) foundation of isolated rat heart Ischemia-Reperfusion Injury Model
SD male rat (Qinglongshan animal rearing center) 250 ± 20g, after the cervical vertebra dislocation, isolate rapidly the K-H liquid that heart places 0 ℃, in, reticular tissue around extravasated blood and the heart in the rapid removing heart, and hang on the isolated heart perfusion instrument, be filled with pure oxygen-saturated K-H liquid perfusion with 37 ℃.Recording ecg.
(2) experiment grouping:
1. ischemic reperfusion K-H liquid perfusion is stablized the left descending branch of following coronary artery occlusion behind the 15min, causes myocardial ischemia, cuts off ligature behind the 20min, fills with again 30min.
2. the sharp special K-H liquid perfusion of Ischemia Reperfusion+Archie is stablized to change behind the 15min and is contained Archie Li Te (1 * 10
-6Mmol/L) K-H liquid changes normal K-H liquid perfusion behind the perfusion 20min, and the left descending branch of following coronary artery occlusion is cut off ligature behind the 20min, fill with again 30min.
3. Ischemia Reperfusion+amiodarone K-H liquid perfusion is stablized to change behind the 15min and is contained amiodarone (1 * 10
-6Mmol/L) K-H liquid changes normal K-H liquid perfusion behind the perfusion 5min, and the left descending branch of following coronary artery occlusion is cut off ligature behind the 20min, fill with again 30min.
4. Ischemia Reperfusion+test compounds (compound 7, compound 22) K-H liquid perfusion is stablized to change behind the 15min and is contained test compounds (compound 7, compound 22) (1 * 10
-6Mmol/L) K-H liquid changes normal K-H liquid perfusion behind the perfusion 20min, and the left descending branch of following coronary artery occlusion is cut off ligature behind the 20min, fill with again 30min.
2. irregular pulse standards of grading
ARR judgement is according to Lambeth meeting standard, the then reference and wait people's code of points of marking. and specific as follows: 0 minute, not normal without the rhythm of the heart; 1 minute, sporadic ventricular premature contraction (referring to the ventricular premature contraction of generation below 3 times in the 1min); 2 minutes, Frequent Premature Ventricular Contractions (referring to the ventricular premature contraction of generation more than 3 times or 3 times in the 1min), premature ventricular beat or premature ventricular beat; 3 minutes, sporadic ventricular tachycardia (referring to the ventricular tachycardia of generation below 3 times in the 1min); 4 minutes, taking place frequently property ventricular tachycardia (referring to the ventricular tachycardia of generation more than 3 times or 3 times in the 1min); 5 minutes, pounced on the chamber; 6 minutes: quiver in the chamber; 7 minutes: quiver to cause death and die in the chamber.
3. experimental result:
Shown in Fig. 5～7; the compounds of this invention 7 (corresponding to embodiment 7) and 22 (corresponding to embodiment 22) have preferably antiarrhythmia activity; can significantly slow down the heart rate (Fig. 5) of irregular pulse pathology rat; the irregular pulse of ischemic stage and multiple flush phase is divided the number average (Fig. 6 that increases after the administration; 7), effect is with to have finished clinical anti-arrhythmic Archie Li Te of III phase in the U.S. suitable.
The above results demonstration, benzene oxyalkyl piperazine compounds of the present invention is for the Delayed Rectifier Potassium Channels electric current I
Kur, I
KrAnd I
KsAll has certain blocking activity, under effective dose: can improve the expression level of atrial fibrillation animal cardiac muscle inserted by connexin Cx43, improve electric signal transmission between the myocardial cell; Can effectively shorten the irregular pulse time length, prolong myocardial cell's effective refractory period (ERP), thereby show the therapeutic action to chamber property and atrial arrhythmia.This compounds and medicinal preparations thereof can be used for the treatment of a series of diseases that cause owing to the potassium-channel dysfunction, for example, and the diseases such as irregular pulse, ischemia injury.
Description of drawings
Fig. 1 is that compound 7 is on impact (the A:Western original graph of atrial fibrillation rat heart muscle Cx43 protein expression level; B: gray scale is quantitatively schemed)
Fig. 2 is the impact of compound 22 on the rat atrial fibrillation time
Fig. 3 is the impact of compound 7 on the rat atrial fibrillation time
Fig. 4 is that compound 7 and compound 22 are on the effect that Fig. 5 is 22 pairs of ventricular arrhythmia pathology of compound rat heart rate that affects of rat atrial ERP
Fig. 6 is the effect of 7 pairs of ventricular arrhythmia pathology of compound rat heart rate
Fig. 7 is the irregular pulse fractional value of each time point of 22 pairs of ventricular arrhythmia pathology rat ischemia phase administrations of compound
Fig. 8 is the irregular pulse fractional value of each time point of 7 pairs of ventricular arrhythmia pathology rat ischemia phase administrations of compound
Fig. 9 is the irregular pulse fractional value of multiple each time point of flush phase administration of 22 pairs of ventricular arrhythmia pathology of compound rat
The irregular pulse fractional value of multiple each time point of flush phase administration of 7 pairs of ventricular arrhythmia pathology of Figure 10 compound rat
Embodiment
Thiophene-2-(4-(2-(4-tolyloxy) ethyl) piperazine) ketone
(1) preparation of 1-piperazine-(2-thiophene) ketone hydrochloride
Thiophene-2-carboxylic acid (0.06mol) is dissolved in methylene dichloride, adds sulfur oxychloride (0.15mol), and 5 ℃ are stirred 2h, is warming up to 40 ℃ and stirs 4h.Solvent evaporated adds dehydrated alcohol (100mL), drips the ethanol solution (40mL) of piperazine (0.12mol), backflow 5h.Solvent evaporated adds water, transfers pH=8～9 with 10% sodium hydroxide solution, chloroform extraction (50mL * 3 time), and organic layer is with anhydrous magnesium sulfate drying.Filter, pass into hydrochloric acid gas, the adularescent solid is separated out, and filters, and dries to get product 2.19g under the infrared lamp, productive rate: 16%, and fusing point: 239-241 ℃.
(2) preparation of 1-(2-bromine oxethyl)-4-methylbenzene
P-methyl phenol (0.06mol) water-soluble (80mL) adds glycol dibromide, backflow 1h drips 25% sodium hydroxide solution, continues backflow 4h, cooling, ethyl acetate extraction (20mL * 3 time), anhydrous sodium sulfate drying, filter solvent evaporated, column chromatography purification, eluent is ethyl acetate: sherwood oil=1: 10, concentrate eluant gets white solid 4.5g, productive rate: 35%, and 50 ℃ of fusing points.
(3) preparation of title compound
1-piperazine-(2-thiophene) ketone hydrochloride (0.0036mol) is dissolved in acetonitrile (15mL), drip triethylamine to entirely molten, add salt of wormwood (0.006mol), backflow 1h, drip the 10mL acetonitrile solution of 1-(2-bromine oxethyl)-4-methylbenzene (0.003mol), backflow 4h filters solvent evaporated, column chromatography purification, eluent is sherwood oil: ethyl acetate=1: 1～1: 4, concentrate eluant, re-crystallizing in ethyl acetate, get white solid, productive rate: 52.5%, fusing point: 84-86 ℃, EI-MS m/z 330 ([M]
+),
1H-NMR (CDCl
3) δ 2.28 (s, 3H ,-PhC
H 3 ), 2.62 (t, 4H, J=5.1Hz ,-N (C
H 2 CH
2)
2NCO-), 2.83 (t, 2H, J=5.7Hz ,-NC
H 2 CH
2O-), 3,77 (t, 4H, J=5.1Hz ,-N (CH
2C
H 2 )
2NCO-), 4.1 (t, 2H, J=5.7Hz ,-NCH
2C
H 2 O-), 6.6.78-6.82 (m, 2H, Ar-H), 7.02-7.09 (m, 2H, Ar-H), 7.23-7.27 (m, 1H, Ar-H), 7.3 (m, 1H, Ar-H).
Thiophene-2-(4-(2-(2-tolyloxy) ethyl) piperazine) ketone hydrochloride
(1) preparation of 1-(2-bromine oxethyl)-4-methylbenzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with ortho-methyl phenol, underpressure distillation gets colorless oil, productive rate: 56.4%.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, 1-(2-bromine oxethyl)-4-methylbenzene substitutes 1-(2-bromine oxethyl)-4-methylbenzene, column chromatography purification, the evaporate to dryness elutriant, add 20mL ethanol, pass into hydrochloric acid gas, productive rate: 45.5%, fusing point: 207-209 ℃, EI-MS m/z 330 ([M]
+),
1H-NMR (D
2O) δ 2.26 (d, 3H ,-PhC
H 3 ), 3,47 (s, 4H ,-N (C
H 2 CH
2)
2NCO-), 3.6 (t, 2H, J=4.5Hz ,-NC
H 2 CH
2O-), 4.05 (s, 4H ,-N (CH
2C
H 2 )
2NCO-), 4.37 (t, 2H, J=4.5Hz ,-NCH
2C
H 2 O-), 6.86-6.92 (m, 3H, Ar-H), 7.12-7.24 (m, 2H, Ar-H), 7.28 (d, 1H, J=3.3 Hz, Ar-H), 7.88 (d, 1H, J=4.8Hz, Ar-H).
Thiophene-2-(4-(2-(4-methoxyphenoxy) ethyl) piperazine) ketone
(1) preparation of 1-(2-bromine oxethyl)-4-anisole
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with p methoxy phenol, productive rate: 39%, fusing point: 51-53 ℃.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(2-bromine oxethyl)-4-anisole, productive rate: 59.7%, fusing point: 82-84 ℃, EI-MS m/z 346 ([M]
+),
1H-NMR (CDCl
3) δ 2.63 (t, 4H, J=4.8Hz ,-N (C
H 2 CH
2)
2NCO-), 2.83 (t, 2H, J=5.4Hz ,-NC
H 2 CH
2O-), 3.79 (t, 7H ,-N (CH
2C
H 2 )
2NCO-,-PhOC
H 3 ), 4.08 (t, 2H, J=5.4Hz ,-NCH
2C
H 2 O-), 6.84 (m, 4H, Ar-H), 7.02-7.06 (m, 1H, Ar-H), 7.26-7.29 (m, 1H,, Ar-H), 7.45 (d, 1H, J=5.1Hz, Ar-H).
Thiophene-2-(4-(2-(4-Trifluoromethyl phenyl ether oxygen base) ethyl) piperazine) ketone hydrochloride
(1) preparation of 1-(2-bromine oxethyl)-4-Trifluoromethyl phenyl ether
Press the preparation of step among the embodiment 1 (2) method, trifluoro-methoxy-phenol is substituted p-methyl phenol, productive rate: 48%, fusing point: 67-69 ℃,
1H-NMR (CDCl
3) δ 3.63 (t, 2H, J=6.3Hz ,-OCH
2C
H 2 -), 4.27 (t, 2H, J=6.3Hz ,-OC
H 2 CH
2-), 6.91 (m, 2H, Ar-H), 7.15 (m, 2H, Ar-H).
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(2-bromine oxethyl)-4-Trifluoromethyl phenyl ether, column chromatography purification, the evaporate to dryness elutriant, add 20mL ethanol, pass into hydrochloric acid gas, productive rate: 73.39%, fusing point: 208-210 ℃, EI-MS m/z 400 ([M]
+),
1H-NMR (D
2O) δ 3.29 (s, 8H,
), 3.43 (t, 2H, J=4.8Hz ,-OCH
2C
H 2 -), 4.17 (t, 2H, J=4.8Hz ,-O
CH 2 CH
2-), 6.78-6.82 (m, 2H, Ar-H), 6.89-6.92 (m, 1H, Ar-H), 7.04 (m, 2H, Ar-H), 7.21 (m, 1H, Ar-H), 7.45 (m, 1H, Ar-H)
4-(2-(4-(thiophene-2-formyl) piperazine) oxyethyl group) cyanophenyl
(1) preparation of 4-(2-bromine oxethyl) cyanophenyl
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with the para hydroxybenzene nitrile, productive rate: 33%, fusing point: 59 ℃.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 4-(2-bromine oxethyl) cyanophenyl, productive rate: 27.1%, fusing point: 131-134 ℃, EI-MS m/z 341 ([M]
+),
1H-NMR (CDCl
3) δ 2.63 (s, 4H ,-N (C
H 2 CH
2)
2NCO-), 2.88 (s, 2H ,-NC
H 2 CH
2O-), 3.78 (s, 4H ,-N (CH
2C
H 2 )
2NCO-), 4.17 (s, 2H ,-NCH
2C
H 2 O-), 6.93-6.98 (m, 2H, Ar-H), 7.03-7.06 (m, 1H, Ar-H), 7.28-7.30 (m, 1H,, Ar-H), 7.44-7.47 (m, 1H, Ar-H), 7.57-7.62 (m, 2H, Ar-H).
Thiophene-2-(4-(2-(4-fluorophenoxy) ethyl) piperazine) ketone hydrochloride
(1) preparation of 1-(2-bromine oxethyl)-4-fluorobenzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with p-fluorophenol, productive rate: 46%, fusing point: 78-80 ℃.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(2-bromine oxethyl)-4-fluorobenzene, column chromatography purification, the evaporate to dryness elutriant, add 20mL ethanol, pass into hydrochloric acid gas, productive rate: 42.3%, fusing point: 228-230 ℃, EI-MS m/z 334 ([M]
+),
1H-NMR (CDCl
3) δ 2.56 (s, 4H ,-N (C
H 2 CH
2)
2NCO-), 2.77 (s, 2H ,-NC
H 2 CH
2O-), 3.71 (s, 4H ,-N (CH
2C
H 2 )
2NCO-), 4.03 (s, 2H ,-NCH
2C
H 2 O-), 6.74-6.80 (m, 2H, Ar-H), 6.85-6.98 (m, 3H, Ar-H), 7.19-7.22 (m, 1H, Ar-H), 7.36-7.38 (m, 1H, Ar-H).
Thiophene-2-(4-(2-(4-chlorophenoxy) ethyl) piperazine) ketone
(1) preparation of 1-(2-bromine oxethyl)-4-chlorobenzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with para-chlorophenol, underpressure distillation gets colourless liquid, productive rate: 53.2%.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(2-bromine oxethyl)-4-chlorobenzene, productive rate: 58.9%, fusing point: 75-77 ℃, EI-MS m/z 350 ([M]
+),
1H-NMR (CDCl
3) δ 2.65 (s, 4H ,-N (C
H 2 CH
2)
2NCO-), 2.87 (s, 2H ,-NC
H 2 CH
2O-), 3.81 (s, 4H ,-N (CH
2C
H 2 )
2NCO-), 4.11 (s, 2H ,-NCH
2C
H 2 O-), 6.81-6.86 (m, 2H, Ar-H), 7.03-7.06 (dd, 1H, J=3.6Hz, 1.2Hz, Ar-H), 7.22-7.30 (m, 3H, Ar-H), 7.52 (d, 1H, J=4.2Hz, Ar-H).
Thiophene-2-(4-(2-(4-bromine phenoxy group) ethyl) piperazine) ketone
(1) preparation of 1-bromo-4-(2-bromine oxethyl) benzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with p bromophenol, underpressure distillation gets colourless liquid, productive rate: 45.7%.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-bromo-4-(2-bromine oxethyl) benzene, productive rate: 37.8%, fusing point: 82-83 ℃, EI-MS m/z 395 ([M]
+),
1H-NMR (CDCl
3) δ 2.62 (t, 4H, J=4.8Hz ,-N (C
H 2 CH
2)
2NCO-), 2.84 (t, 2H, J=5.4Hz ,-NC
H 2 CH
2O-), 3.78 (t, 4H ,-N (CH
2C
H 2 )
2NCO-), 4.08 (t, 2H, J=5.4Hz ,-NCH
2C
H 2 O-), 6.77-6.8 (m, 2H, Ar-H), 7.01-7.06 (m, 1H, Ar-H), 7.28-7.29 (m, 1H,, Ar-H), 7.32-7.36 (m, 2H, Ar-H), 7.44-7.46 (m, 1H, Ar-H).
Embodiment 9
Thiophene-2-(4-(2-(2-chlorophenoxy) ethyl) piperazine) ketone hydrochloride
(1) preparation of 1-(2-bromine oxethyl)-2-chlorobenzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with ortho chloro phenol, underpressure distillation gets colourless liquid, productive rate: 44%.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(2-bromine oxethyl)-2-chlorobenzene, column chromatography purification, the evaporate to dryness elutriant, add 20mL ethanol, pass into hydrochloric acid gas, productive rate: 81.0%, fusing point: 204-206 ℃, EI-MS m/z 350 ([M]
+),
1H-NMR (D
2O) δ 3.58 (s, 4H ,-N (C
H 2 CH
2)
2NCO-), 3,71 (t, 2H, J=4.5Hz ,-NC
H 2 CH
2O-), 4.06 (s, 4H ,-N (CH
2C
H 2 )
2NCO-), 4.47 (t, 2H, J=4.5Hz ,-NCH
2C
H 2 O-), 6.81-6.86 (m, 2H, Ar-H), 7.00-7.06 (m, 1H, Ar-H), (7.09-7.15 m, 2H, Ar-H), 7.28-7.34 (m, 1H, Ar-H), 7.43-7.46 (m, 2H, Ar-H), 7.68 (d, 1H, J=5.1Hz, Ar-H).
Thiophene-2-(4-(2-(2,4 dichloro benzene oxygen base) ethyl) piperazine) ketone
(1) preparation of 1-(2-bromine oxethyl)-2,4 dichloro benzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with ortho chloro phenol, underpressure distillation gets colourless liquid, productive rate: 49.8%.
(2) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(2-bromine oxethyl)-2,4 dichloro benzene, productive rate: 53.5%, fusing point: 67-68 ℃, EI-MS m/z 386 ([M]
+),
1H-NMR (CDCl
3) δ 2.68 (t, 4H, J=4.5Hz ,-N (C
H 2 CH
2)
2NCO-), 2.91 (t, 2H, J=5.1Hz ,-NC
H 2 CH
2O-), 3,78 (t, 4H, J=4.5Hz ,-N (CH
2C
H 2 )
2NCO-), 4.16 (t, 2H, J=5.1Hz ,-NCH
2C
H 2 O-), 6.52 (d, 1H, J=8.7Hz, Ar-H), 7.03-7.06 (m, 1H, Ar-H), 7.16-7.20 (m, 1H, Ar-H), 7.28-7.30 (m, 1H, Ar-H), (7.36 d, 1H, J=2.7Hz, Ar-H), 7.44-7.46 (m, 1H, Ar-H).
Embodiment 11
2-(4-(2-benzene oxygen ethyl) piperazine)-N-(2-thiazole)-ethanamide dihydrochloride
(1) preparation of 2-chloro-N-(2-thiazole)-ethanamide
Thiazolamine (0.02mol) is dissolved in DMF (40mL); add triethylamine (0.02mol); drip the DMF solution of chloroacetyl chloride (0.024mol); stirring at room 2h under the nitrogen protection adds water (160mL), filters; dry to get faint yellow solid 2.68g under the infrared lamp; productive rate: 75.9%, fusing point: 171-173 ℃, EI-MS m/z 176 ([M]
+),
1H-NMR (CDCl
3) δ 4.38 (s, 2H ,-NHCOC
H 2 Cl-), 7.27 (d, 1H, J=3.3Hz,
), 7.49 (d, 1H, J=3.3Hz,
), 12.47 (s, 1H ,-N
HCO-).
(2) preparation of 1-(2-benzene oxygen ethyl) piperazine dihydrochloride
Piperazine (0.08mol) is dissolved in ethanol (50mL), drip equivalent 40% hydrobromic acid aqueous solution, stirring at room 15min, the 20mL ethanol of dropping 2-bromine oxethyl benzene (0.04mol), backflow 6h, be chilled to room temperature, filter, the filtrate evaporate to dryness adds water, transfer pH=8～9 with 10% sodium hydroxide solution, chloroform extraction (50mL * 3 time), organic layer filter with anhydrous magnesium sulfate drying, filtrate is to original volume 1/5, pass into hydrochloric acid gas, get white solid, 95% ethyl alcohol recrystallization, productive rate: 52.1%, fusing point: 197 ℃ (dec).
(3) preparation of title compound
1-(2-benzene oxygen ethyl) piperazine dihydrochloride (0.005mol) is dissolved in DMF, add salt of wormwood (0.01mol), drip the DMF solution of 2-chloro-N-(2-thiazole)-ethanamide, 60 ℃ are stirred 5h, in reaction solution impouring water, and chloroform extraction (20mL * 3 time), organic layer is with anhydrous sodium sulfate drying, the evaporate to dryness organic layer, column chromatography purification, eluent are ethyl acetate: sherwood oil=3: 1, the evaporate to dryness eluent, add 10mL ethanol, pass into hydrochloric acid gas, get white solid, with 95% ethyl alcohol recrystallization, productive rate: 11.9%, fusing point: 226-228 ℃, EI-MS m/z 346 ([M]
+),
1H-NMR (D
2O) δ 3.25 (s, 4H ,-COCH
2N (CH
2C
H 2 ) 2 N-), 3.58-3.85 (m, 8H ,-COCH
2N (C
H 2 CH
2)
2N-,-NC
H 2 CH
2O-,-NHCOC
H 2 N-), 4.35 (t, 2H, J=4.5Hz ,-NCH
2C
H 2 O-), 6.95-7.03 (m, 4H, Ar-H), 7.19-7.22 (m, 1H, Ar-H), 7.31 (m, 2H, Ar-H), 7.44-7.46 (m, 1H, Ar-H).
Embodiment 12
N-(2-thiazole)-2-(4-(2-(4-methylphenoxy) ethyl) piperazine) ethanamide
(1) 1-(preparation of 2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 1-(2-bromine oxethyl)-4-methylbenzene, productive rate: 58.1%, fusing point: 203 ℃ (dec).
(2) preparation of title compound
1-(2-benzene oxygen ethyl) piperazine dihydrochloride (0.005mol) is dissolved in DMF, add salt of wormwood (0.01mol), drip the DMF solution of 2-chloro-N-(2-thiazole)-ethanamide, 60 ℃ are stirred 5h, in reaction solution impouring water, chloroform extraction (20mL * 3 time), organic layer is with anhydrous sodium sulfate drying, the evaporate to dryness organic layer, column chromatography purification, eluent are ethyl acetate: sherwood oil=3: 1, the evaporate to dryness eluent, productive rate: 43.3%, fusing point: 103-105 ℃, EI-MS m/z 360 ([M]
+),
1H-NMR (CDCl
3) δ 2.68 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 2.83 (t, 2H, J=5.7Hz ,-NC
H 2 CH
2O-), 3,25 (s, 2H ,-NHCOC
H 2 N-), 4.08 (t, 2H, J=5.7Hz ,-NCH
2C
H 2 O-), 6.78-6.83 (m, 2H, Ar-H), 6.99 (d, 1H, J=3.6Hz,
), 7.06 (s, 1H, Ar-H) 7.09 (s, 1H, Ar-H), 7.46 (d, 1H, J=3.6Hz,
), 10.32 (s, 1H,
).
Embodiment 13
N-(2-thiazole)-2-(4-(2-(2-methylphenoxy) ethyl) piperazine) ethanamide
(1) 1-(preparation of 2-(2-methylenedioxy phenoxy ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 1-(2-bromine oxethyl)-2-methylbenzene, productive rate: 30.9%, fusing point: 236 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 12 (2) method, (2-(2-methylenedioxy phenoxy ethyl) piperazine dihydrochloride substitutes 1-(2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride with 1-, productive rate: 43.3%, fusing point: 103-105 ℃, EI-MS m/z 360 ([M]
+),
1H-NMR (CDCl
3) δ 2.22 (s, 3H ,-PhC
H 3 ) 2.69 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 2.88 (t, 2H, J=5.7Hz ,-NC
H 2 CH
2O-), 3,26 (s, 2H ,-NHCOC
H 2 N-), 4.12 (t, 2H, J=5.7Hz ,-NCH
2C
H 2 O-), 6.79-6.86 (m, 2H, Ar-H), 7.00 (d, 1H, J=3.6Hz,
(7.12-7.17 m, 2H, Ar-H), 7.46 (d, 1H, J=3.6Hz,
), 10.33 (s, 1H,
).
Embodiment 14
N-(2-thiazole)-2-(4-(2-(2,4-dimethyl phenoxy) ethyl) piperazine) ethanamide dihydrochloride
(1) 1-(preparation of 2-(2,4-dimethyl benzene oxygen ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, with 1-(2-bromine oxethyl)-2, the 4-dimethyl benzene substitutes 2-bromine oxethyl benzene, productive rate: 29.7%, and fusing point: 240 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, (2-(2,4-dimethyl benzene oxygen ethyl) piperazine dihydrochloride substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, productive rate: 48.5% with 1-, fusing point: 215-217 ℃, EI-MS m/z 374 ([M]
+),
1H-NMR (D
2O) δ 2.13 (s, 3H,
), 2.18 (s, 3H,
) 2.35 (t, 2H, J=4.2Hz ,-NC
H 2 CH
2O-), 3.68-3.78 (m, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 3,93 (s, 2H ,-NHCOC
H 2 N-), 4,34 (t, 2H, J=4.2Hz ,-NCH
2C
H 2 O-), 6.82-6.86 (m, 1H, Ar-H), 7.00-7.04 (m, 2H, Ar-H), 7.25 (d, 1H, J=3.9Hz,
), 7.48-7.50 (d, 1H, J=3.9Hz,
).
N-(2-thiazole)-2-(4-(2-(3,4-dimethyl phenoxy) ethyl) piperazine) ethanamide dihydrochloride
(1) 1-(preparation of 2-(3,4-dimethyl benzene oxygen ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, with 1-(2-bromine oxethyl)-3, the 4-dimethyl benzene substitutes 2-bromine oxethyl benzene, productive rate: 29.1%, and fusing point: 229 ℃ (dec)
(2) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, (2-(3,4-dimethyl benzene oxygen ethyl) piperazine dihydrochloride substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, productive rate: 21.2% with 1-, fusing point: 213-215 ℃, EI-MS m/z 374 ([M]
+),
1H-NMR (CDCl
3) δ 2.16 (d, 6H,
), 2.68 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-) 2.87 (t, 2H, J=5.7Hz ,-NC
H 2 CH
2O-), 3,25 (s, 2H ,-NHCOC
H 2 N-), 4,08 (t, 2H, J=5.7Hz ,-NCH
2C
H 2 O-), 6.62-6.72 (m, 2H, Ar-H), 6.99-7.04 (m, 2H, Ar-H), 7.45-7.47 (d, 1H, J=3.6Hz,
).
Embodiment 16
N-(2-thiazole)-2-(4-(2-(2,6-dimethyl phenoxy) ethyl) piperazine) ethanamide dihydrochloride
(1) 1-(preparation of 2-(2,6-dimethyl benzene oxygen ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, with 1-(2-bromine oxethyl)-2, the 6-dimethyl benzene substitutes 2-bromine oxethyl benzene, productive rate: 42.1%, and fusing point: 235 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, (2-(2,6-dimethyl benzene oxygen ethyl) piperazine dihydrochloride substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, productive rate: 27.6% with 1-, fusing point: 238-240 ℃, EI-MS m/z 374 ([M]
+),
1H-NMR (DMSO) δ 2.08 (s, 3H ,-PhC
H 3 ), 2.27 (s, 3H ,-PhC
H 3 ), 3.51 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-) 3.62 (s, 2H ,-NC
H 2 CH
2O-), 4.02 (s, 2H ,-NHCOC
H 2 N-), 4,19 (s, 2H ,-NCH
2C
H 2 O-), 6.92-7.06 (m, 3H, Ar-H), 7.30 (d, 1H, J=3.6Hz,
), 7.53 (d, 1H, J=3.6Hz,
)
Embodiment 17
N-(2-thiazole)-2-(4-(2-(4-tertiary butyl phenoxy group) ethyl) piperazine) ethanamide
(1) 1-(preparation of 2-(4-tert.-butylbenzene oxygen ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 1-(2-bromine oxethyl)-4-tert.-butylbenzene, productive rate: 41.3%, fusing point: 252 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 12 (2) method, (2-(4-tert.-butylbenzene oxygen ethyl) piperazine dihydrochloride substitutes 1-(2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride with 1-, productive rate: 46.8%, fusing point: 111-113 ℃, EI-MS m/z 402 ([M]
+),
1H-NMR (CDCl
3) δ 1.30 (s, 9H ,-C (C
H 3 ) 3 ), 2.68 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-) 2.96 (s, 2H ,-NC
H 2 CH
2O-), 3.26 (s, 2H ,-NHCOC
H 2 N-), 4,09 (s, 2H ,-NCH
2C
H 2 O-), 6.82-6.87 (m, 2H, Ar-H), 7.00 (d, 1H, J=3.6Hz,
), 7.28-7.33 (m, 2H, Ar-H), 7.46 (d, 1H, J=3.6Hz,
), 10.32 (s, 1H,
).
Embodiment 18
N-(2-thiazole)-2-(4-(2-(4-methoxyphenoxy) ethyl) piperazine) ethanamide
(1) 1-(preparation of 2-(4-anisole oxygen ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 1-(2-bromine oxethyl)-4-anisole, productive rate: 32.5%, fusing point: 215 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 12 (2) method, (2-(4-tert.-butylbenzene oxygen ethyl) piperazine dihydrochloride substitutes 1-(2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride with 1-, productive rate: 66.5%, fusing point: 102-103 ℃, EI-MS m/z 376 ([M]
+),
1H-NMR (CDCl
3) δ 2.68 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 2.82 (t, 2H, J=5.7Hz ,-NC
H 2 CH
2O-), 3.26 (s, 2H ,-NHCOC
H 2 N-), 3.77 (s, 2H ,-OC
H 3 ), 4.06 (t, 2H, J=5.7Hz ,-NCH
2C
H 2 O-), 6.87 (m, 4H, Ar-H), 7.00 (d, 1H, J=3.3Hz,
), 7.46 (d, 1H, J=3.3Hz,
), 10.32 (s, 1H,
).
Embodiment 19
N-(2-thiazole)-2-(4-(2-(4-Trifluoromethyl phenyl ether oxygen base) ethyl) piperazine) ethanamide
(1) 1-(preparation of 2-(4-Trifluoromethyl phenyl ether oxygen ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 1-(2-bromine oxethyl)-4-Trifluoromethyl phenyl ether, productive rate: 60.4%, fusing point: 223-225 ℃,
1H-NMR (D
2O) δ 3.58 (t, 4H, J=5.4Hz, HN (C
H 2 CH
2)
2N-), 3.68 (m, 6H ,-N (C
H 2 CH
2)
2NH ,-OCH
2C
H 2 -), 4.36 (t, 2H, J=4.8Hz ,-OC
H 2 CH
2-), 6.98-7.03 (m, 2H, Ar-H), 7.22-7.26 (m, 2H, Ar-H).
(2) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, (2-(4-Trifluoromethyl phenyl ether oxygen ethyl) piperazine dihydrochloride substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride with 1-, productive rate: 73.4%, fusing point: 225 ℃, EI-MS m/z 430 ([M]
+),
1H-NMR (D
2O) δ 3.15 (s, 4H ,-N (C
H 2 CH
2)
2NCH
2CO-), 3.55 (s, 4H ,-N (CH
2C
H 2 ) 2 NCH
2CO-), 3.64 (t, 2H, J=4.2Hz ,-NC
H 2 CH
2O-), 3.72 (s, 2H ,-NHCOC
H 2 N-), 4.38 (t, 2H, J=4.2Hz ,-NCH
2C
H 2 O-), 7.03 (d, 2H, Ar-H), 7.21-7.28 (m, 3H, Ar-H), 7.46 (d, 1H, J=3.9Hz,
).
N-(2-thiazole)-2-(4-(2-(2-ethoxy phenoxy) ethyl) piperazine) ethanamide
(1) 1-(preparation of 2-(2-phenoxy ethoxy ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 1-(2-bromine oxethyl)-2-phenetole, productive rate: 37.1%, fusing point: 214 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 12 (2) method, (2-(2-phenoxy ethoxy ethyl) piperazine dihydrochloride substitutes 1-(2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride with 1-, productive rate: 78.5%, fusing point: 90-92 ℃, EI-MS m/z 390 ([M]
+),
1H-NMR (CDCl
3) δ 1.42 (t, 3H, J=6.9Hz ,-OCH
2C
H 3 ), 2.68 (s, 8H ,-N (
CH 2 CH 2 ) 2 NCH
2CO-), 2.87 (t, 2H, J=5.7Hz ,-NC
H 2 CH
2O-), 3.25 (s, 2H ,-NHCOC
H 2 N-), 4.05 (q, 2H, J=6.9Hz ,-OC
H 2 CH
3), 4.14 (t, 2H, J=5.7Hz ,-NCH
2C
H 2 O-), 6.89 (s, 4H, Ar-H), 6.99 (d, 1H, J=3.6Hz,
), 7.45 (d, 1H, J=3.6Hz,
), 10.33 (s, 1H,
).
Embodiment 21
N-(2-thiazole)-2-(4-(2-(2-chlorophenoxy) ethyl) piperazine) ethanamide
(1) 1-(preparation of 2-(2-chlorobenzene oxygen ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 1-(2-bromine oxethyl)-2-chlorobenzene, productive rate: 43.0%, fusing point: 229 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 12 (2) method, (2-(2-chlorobenzene oxygen ethyl) piperazine dihydrochloride substitutes 1-(2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride with 1-, productive rate: 45.0%, fusing point: 218-220 ℃, EI-MS m/z 380 ([M]
+),
1H-NMR (D
2O) δ 3.18 (s, 2H ,-NC
H 2 CH
2O-), 3.57-3.76 (m, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 3.86 (s, 2H ,-NHCOC
H 2 N-), 4.54 (s, 2H ,-NCH
2C
H 2 O-), 6.98-7.46 (m, 6H, Ar-H).
2-(4-(2-(4-itrile group phenoxy group) ethyl) piperazine)-N-(2-thiazole) ethanamide
(1) preparation of 4-(2-(1-piperazine) oxyethyl group) cyanophenyl dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 4-(2-bromine oxethyl) cyanophenyl, productive rate: 69.4%, fusing point: 212-215 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 12 (2) method, 4-(2-(1-piperazine) oxyethyl group) cyanophenyl dihydrochloride substitutes 1-(2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride, productive rate: 52.6%, fusing point: 185-187 ℃, EI-MS m/z 371 ([M]
+),
1H-NMR (CDCl
3) δ 2.68 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 2.87 (t, 2H, J=4.5Hz ,-NC
H 2 CH
2O-), 3.26 (s, 2H ,-NHCOC
H 2 N-), 4.13 (t, 2H, J=4.5Hz ,-NCH
2C
H 2 O-), 6.96 (d, 2H, J=8.7Hz, Ar-H), 6.99 (d, 1H, J=3.3Hz,
), 7.45 (d, 1H, J=3.3Hz,
), 7.59 (d, 2H, J=8.7Hz, Ar-H), 10.28 (s, 1H,
).
Embodiment 23
2-(4-(2-(2-naphthyloxy) ethyl) piperazine)-N-(2-thiazole) ethanamide
(1) preparation of 1-(2-(2-naphthyloxy) ethyl) piperazine dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 2-(2-bromine oxethyl) naphthalene, productive rate: 39.9%, fusing point: 233 ℃ (dec).
(2) preparation of title compound
Press the preparation of step among the embodiment 12 (2) method, 1-(2-(2-naphthyloxy) ethyl) piperazine dihydrochloride substitutes 1-(2-(4-methylenedioxy phenoxy ethyl) piperazine dihydrochloride, productive rate: 64.6%, fusing point: 119-121 ℃, EI-MS m/z 396 ([M]
+),
1H-NMR (CDCl
3) δ 2.71 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 2.94 (t, 2H, J=5.4Hz ,-NC
H 2 CH
2O-), 3.27 (s, 2H ,-NHCOC
H 2 N-), 4.25 (t, 2H, J=5.4Hz ,-NCH
2C
H 2 O-), 7.00-7.78 (m, 9H, Ar-H), 10.34 (s, 1H,
).
Embodiment 24
4-(2-(4-(2-oxo-2-(thiazolamine) ethyl) piperazine) oxyethyl group) ethyl benzoate dihydrochloride
(1) preparation of 4-(2-(1-piperazine) oxyethyl group) ethyl benzoate dihydrochloride
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene with 4-(2-bromine oxethyl) ethyl benzoate, productive rate: 42%, fusing point: 232-234 ℃ (dec), EI-MS m/z 274 ([M]
+),
1H-NMR (CDCl
3) δ 1.30 (t, 3H, J=7.2Hz ,-CH
2C
H 3 ), 2.51 (s, 4H, HN (C
H 2 CH
2)
2N-), 2.56 ((s, 4H,
HN (C
H 2 CH
2)
2N-), 2.74 (t, 3H, J=7.2Hz ,-CH
2 C
H 2 N-), 2.86 (t, 4H ,-N (C
H 2 CH
2)
2NH), 4.08 (t, 2H, J=5.7Hz ,-OC
H 2 CH
2N-), 4.26 (q, 2H ,-OC
H 2 CH
3), 6.82-6.86 (d, J=9Hz, 2H, Ar-H), 7.90-7.93 (d, J=9Hz, 2H, Ar-H).
(2) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, 4-(2-(1-piperazine) oxyethyl group) ethyl benzoate dihydrochloride substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, productive rate: 44.5%, fusing point: 216-218 ℃, EI-MS m/z 418 ([M]
+),
1H-NMR (CDCl
3) δ 1.26 (t, 3H, J=3.3Hz ,-CH
2C
H 3 ), 2.68 (s, 8H ,-N (C
H 2 C
H 2 ) 2 NCH
2CO-), 2.87 (t, 2H, J=5.7Hz ,-NC
H 2 CH
2O-), 3.26 (s, 2H ,-NHCOC
H 2 N-), 4.16 (t, 2H, J=5.4Hz ,-NCH
2C
H 2 O-), 4.31-4.38 (q, 3H ,-OC
H 3 ), 6.90-6.93 (d, 2H, J=9Hz, Ar-H), 7.00 (d, 1H, J=3.6Hz), 7.46 (d, 1H, J=3.9Hz,
), 7.98-8.01 (d, J=9Hz, 2H, Ar-H), 10.33 (s, 1H,
).
(4-chloro-phenyl-) (4-(2-(2,3,5-trimethylammonium phenoxy group) ethyl) piperazine-1-yl) ketone
(1) preparation of 1-piperazine-(4-chlorobenzene) ketone hydrochloride
4-chloro-benzoic acid (0.06mol) is dissolved in methylene dichloride, adds sulfur oxychloride (0.15mol), and 5 ℃ are stirred 2h, is warming up to 40 ℃ and stirs 4h.Solvent evaporated adds dehydrated alcohol (100mL), drips the ethanol solution (40mL) of piperazine (0.12mol), backflow 5h.Solvent evaporated adds water, transfers pH=8～9 with 10% sodium hydroxide solution, chloroform extraction (50mL * 3 time), and organic layer is with anhydrous magnesium sulfate drying.Filter, pass into hydrochloric acid gas, the adularescent solid is separated out, and filters, and dries to get product 2.69g under the infrared lamp, productive rate: 20%.
(2) 1-(2-bromine oxethyl)-2,3, the preparation of 5-Three methyl Benzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with 2,3,5-TEP, underpressure distillation gets colourless liquid, productive rate: 49.8%.
(3) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, with 1-(2-bromine oxethyl)-2,3, the 5-Three methyl Benzene substitutes 1-(2-bromine oxethyl)-4-methylbenzene, 1-piperazine-(4-chlorobenzene) ketone hydrochloride substitutes 1-piperazine-(2-thiophene) ketone hydrochloride, productive rate: 49.5%, EI-MS m/z387 ([M]
+),
1H-NMR (CDCl
3) δ 2.08 (s, 3H), 2.34 (s, 6H), 2.55 (t, 4H), 2.76 (t, 2H), 3.78 (t, 4H), 4.16 (t, 2H), 6.54 (d, 1H), (6.70 d, 1H), 7.67 (d, 2H), 7.97 (d, 2H).
Embodiment 26
(4-chloro-phenyl-) (4-(2-(4-4-trifluoromethylphenopendant) ethyl) piperazine-1-yl) ketone
(1) preparation of 1-piperazine-(4-chlorobenzene) ketone hydrochloride
4-chloro-benzoic acid (0.06mol) is dissolved in methylene dichloride, adds sulfur oxychloride (0.15mol), and 5 ℃ are stirred 2h, is warming up to 40 ℃ and stirs 4h.Solvent evaporated adds dehydrated alcohol (100mL), drips the ethanol solution (40mL) of piperazine (0.12mol), backflow 5h.Solvent evaporated adds water, transfers pH=8～9 with 10% sodium hydroxide solution, chloroform extraction (50mL * 3 time), and organic layer is with anhydrous magnesium sulfate drying.Filter, pass into hydrochloric acid gas, the adularescent solid is separated out, and filters, and dries to get product 2.69g under the infrared lamp, productive rate: 20%.
(2) preparation of 1-(2-bromine oxethyl)-4-trifluoromethylbenzene
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with the 4-trifloro methyl phenol, underpressure distillation gets colourless liquid, productive rate: 37.5%.
(3) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(2-bromine oxethyl)-4-trifluoromethylbenzene, 1-piperazine-(4-chlorobenzene) ketone hydrochloride substitutes 1-piperazine-(2-thiophene) ketone hydrochloride, productive rate: 49.5%, EI-MS m/z413 ([M]
+),
1H-NMR (CDCl
3) δ 2.55 (t, 4H), 2.76 (t, 2H), 3.44 (t, 4H), 4.11 (t, 2H), 6.92 (d, 1H), 7.51 (d, 2H), 7.89 (d, 2H), 8.10 (d, 2H).
Embodiment 27
4-(4-(4-(furans-2-formyl radical) piperazine-1-yl) butoxy) cyanophenyl
(1) preparation of 1-piperazine-(2-furans) ketone hydrochloride
2-furancarboxylic acid (0.06mol) is dissolved in methylene dichloride, adds sulfur oxychloride (0.15mol), and 5 ℃ are stirred 2h, is warming up to 40 ℃ and stirs 4h.Solvent evaporated adds dehydrated alcohol (100mL), drips the ethanol solution (40mL) of piperazine (0.12mol), backflow 5h.Solvent evaporated adds water, transfers pH=8～9 with 10% sodium hydroxide solution, chloroform extraction (50mL * 3 time), and organic layer is with anhydrous magnesium sulfate drying.Filter, pass into hydrochloric acid gas, the adularescent solid is separated out, and filters, and dries to get product 2.81g under the infrared lamp, productive rate: 26%.
(2) preparation of 1-(4-bromine butoxy)-4-cyanophenyl
Press the preparation of step among the embodiment 1 (2) method, substitute p-methyl phenol with the 4-cyanophenol, underpressure distillation gets colourless liquid, productive rate: 68%.
(3) preparation of title compound
Press the preparation of step among the embodiment 1 (3) method, substitute 1-(2-bromine oxethyl)-4-methylbenzene with 1-(4-bromine butoxy)-4-cyanophenyl, 1-piperazine-(2-furans) ketone hydrochloride substitutes 1-piperazine-(2-thiophene) ketone hydrochloride, productive rate: 42.5%, EI-MS m/z 353 ([M]
+),
1H-NMR (CDCl
3) δ 1.36 (m, 2H), 1.76 (m, 2H), (2.51 t, 4H), 3.01 (t, 2H), (3.34 t, 4H), 4.16 (t, 2H), (6.83 d, 1H), 7.17～7.27 (m, 3H), (7.51 d, 2H), 7.79 (d, 2H), 8.19 (d, 1H).
Embodiment 28
2-(4-(2-(4-chlorophenoxy) ethyl) piperazine-1-yl)-N-(3,5-3,5-dimethylphenyl) ethanamide
(1) preparation of 2-chloro-N-(3,5-3,5-dimethylphenyl) ethanamide
3; 5-xylidine (0.02mol) is dissolved in DMF (40mL); add triethylamine (0.02mol); drip the DMF solution of chloroacetyl chloride (0.024mol); stirring at room 2h under the nitrogen protection adds water (160mL), filters; dry to get faint yellow solid 3.16g under the infrared lamp, productive rate: 80%.
(2) preparation of 4-(2-(1-piperazine) oxyethyl group) chlorobenzene
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene, productive rate: 31% with 4-(2-bromine oxethyl) chlorobenzene.
(3) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, 4-(2-(1-piperazine) oxyethyl group) chlorobenzene substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, 2-chloro-N-(3, the 5-3,5-dimethylphenyl) ethanamide substitutes 2-chloro-N-(2-thiazole)-ethanamide, productive rate: 48%, EI-MS m/z402 ([M]
+),
1H-NMR (CDCl
3) δ 2.34 (s, 6H), 2.51 (s, 8H), 2.76 (t, 2H), 3.34 (s, 2H), 4.11 (t, 2H), 7.03 (d, 2H), 7.09 (t, 2H), 7.23 (s, 1H), 7.35-7.38 (m, 4H).
Embodiment 29
2-(4-(4-(4-chlorophenoxy) butyl) piperazine-1-yl)-N-(4-isopropyl phenyl) ethanamide
(1) preparation of 2-chloro-N-(4-isopropyl phenyl) ethanamide
4-isopropyl aniline (0.02mol) is dissolved in DMF (40mL); add triethylamine (0.02mol); drip the DMF solution of chloroacetyl chloride (0.024mol); stirring at room 2h under the nitrogen protection; add water (160mL); filter, dry to get faint yellow solid 3.05g under the infrared lamp, productive rate: 72%.
(2) preparation of 4-(2-(1-piperazine) butoxy) chlorobenzene
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene, productive rate: 34% with 4-(2-bromine butoxy) chlorobenzene.
(3) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, 4-(2-(1-piperazine) butoxy) chlorobenzene substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, 2-chloro-N-(4-isopropyl phenyl) ethanamide substitutes 2-chloro-N-(2-thiazole)-ethanamide, productive rate: 43%, EI-MS m/z444 ([M]
+),
1H-NMR (CDCl
3) δ 1.21 (s, 6H), 1.36 (q, 2H), 1.76 (q, 2H), 2.35 (s, 8H), 2.87 (q, 1H), (3.01 t, 2H), 3.34 (s, 2H), (4.06 t, 2H), 7.03 (d, 2H), 7.23～7.28 (t, 3H), 7.35-7.38 (m, 4H), (7.45 d, 2H), 7.89 (d, 2H).
2-(4-(4-(2,4-dimethyl phenoxy) butyl) piperazine-1-yl)-N-(1H-imidazoles-2-yl) ethanamide
(1) preparation of 2-chloro-N-(1H-imidazoles-2-yl) ethanamide
2-aminooimidazole (0.02mol) is dissolved in DMF (40mL); add triethylamine (0.02mol); drip the DMF solution of chloroacetyl chloride (0.024mol); stirring at room 2h under the nitrogen protection; add water (160mL); filter, dry to get faint yellow solid 2.23g under the infrared lamp, productive rate: 70%.
(2) preparation of 1-(4-(2,4-dimethyl phenoxy) butyl) piperazine
Press the preparation of step among the embodiment 11 (2) method, with 1-(3-bromine butoxy)-2, the 4-dimethyl benzene substitutes 2-bromine oxethyl benzene, productive rate: 51%.
(3) preparation of title compound
(4-(2 to prepare 1-by step (3) method among the embodiment 11, the 4-dimethyl phenoxy) butyl) piperazine substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, 2-chloro-N-(1H-imidazoles-2-yl) ethanamide substitutes 2-chloro-N-(2-thiazole)-ethanamide, productive rate: 47%, EI-MSm/z 385 ([M]
+),
1H-NMR (CDCl
3) δ 1.42 (q, 2H), 1.85 (q, 2H), 2.15 (s, 3H), 2.34 (s, 3H), 3.11 (t, 2H), 3.29 (s, 2H), 4.15 (t, 2H), (6.75 d, 1H), 6.93～7.02 (m, 4H), 9.15 (s, 1H).
Embodiment 31
N-(3-chloro-5-trifluoromethylpyridine-2-yl)-2-(4-(2-(4-fluorophenoxy) ethyl) piperazine-1-yl) ethanamide
(1) preparation of 2-chloro-N-(3-chloro-5-trifluoromethylpyridine-2-yl) ethanamide
2-amido-3-5-trifluoro picoline (0.02mol) is dissolved in DMF (40mL); add triethylamine (0.02mol); drip the DMF solution of chloroacetyl chloride (0.024mol); stirring at room 2h under the nitrogen protection; add water (160mL); filter, dry to get faint yellow solid 3.28g under the infrared lamp, productive rate: 60%.
(2) preparation of 4-(2-(1-piperazine) oxyethyl group) fluorobenzene
Press the preparation of step among the embodiment 11 (2) method, substitute 2-bromine oxethyl benzene, productive rate: 31% with 4-(2-bromine oxethyl) fluorobenzene.
(3) preparation of title compound
Press the preparation of step among the embodiment 11 (3) method, 4-(2-(1-piperazine) oxyethyl group) fluorobenzene substitutes 1-(2-benzene oxygen ethyl) piperazine dihydrochloride, 2-chloro-N-(3-chloro-5-trifluoromethylpyridine-2-yl) ethanamide substitutes 2-chloro-N-(2-thiazole)-ethanamide, productive rate: 48%, EI-MS m/z 461 ([M]
+),
1H-NMR (CDCl
3) δ 2.34 (s, 8H), 2.76 (d, 2H), 3.29 (d, 2H), 4.11 (d, 2H), 7.09～7.13 (m, 4H), 8.06 (s, 1H), 8.99 (s, 1H), 9.15 (s, 1H).
Claims (4)
1. a benzene oxyalkyl piperazine compounds or its pharmacy acceptable salt is characterized in that having following structure:
2. pharmaceutical composition wherein contains compound or its pharmacy acceptable salt and the pharmaceutically acceptable carrier of claim 1.
3. the compound of claim 1 is for the preparation of the purposes of the medicine of the treatment disease relevant with the potassium-channel dysfunction.
4. the purposes of claim 3, wherein the disease relevant with the potassium-channel dysfunction is irregular pulse or ischemia injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110170726 CN102285962B (en) | 2011-06-23 | 2011-06-23 | Phenoxy alkyl piperazine compounds, preparation method thereof and medicinal use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110170726 CN102285962B (en) | 2011-06-23 | 2011-06-23 | Phenoxy alkyl piperazine compounds, preparation method thereof and medicinal use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102285962A CN102285962A (en) | 2011-12-21 |
| CN102285962B true CN102285962B (en) | 2013-04-10 |
Family
ID=45332738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110170726 Active CN102285962B (en) | 2011-06-23 | 2011-06-23 | Phenoxy alkyl piperazine compounds, preparation method thereof and medicinal use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102285962B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017181004A1 (en) * | 2016-04-14 | 2017-10-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective d3 dopamine receptor agonists and methods of their use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766125A (en) * | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
| CN1944424A (en) * | 2006-10-27 | 2007-04-11 | 中国药科大学 | Aryl formyl piperazine compound and its preparing method and use in medicine production |
-
2011
- 2011-06-23 CN CN 201110170726 patent/CN102285962B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766125A (en) * | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
| CN1944424A (en) * | 2006-10-27 | 2007-04-11 | 中国药科大学 | Aryl formyl piperazine compound and its preparing method and use in medicine production |
Non-Patent Citations (3)
| Title |
|---|
| Medicinal Chemistry Letters》.2000,第10卷p2819-2823. * |
| Ramesh M.Kanojia, et al.."Synthesis and Class III Type Antiarrhythmic Activity of 4-Aroyl (and Aryl)-1-aralkylpiperazines".《Bioorganic & Medicinal Chemistry Letters》.2000,第10卷p2819-2823. |
| Ramesh M.Kanojia, et al.."Synthesis and Class III Type Antiarrhythmic Activity of 4-Aroyl (and Aryl)-1-aralkylpiperazines".《Bioorganic & * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102285962A (en) | 2011-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5231229B2 (en) | Substituted 4-phenyltetrahydroisoquinolines, methods for their preparation, their use as drugs, and drugs containing them | |
| KR100195809B1 (en) | Serotonin receptors agents | |
| CN104010501B (en) | Containing SRC homologous region 2 albumen Tyrosine phosphatase-1 synergist and methods of treatments thereof | |
| EP2725018B1 (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
| CN104761509A (en) | Fibrosis inhibitor | |
| CN105392785B (en) | 1,3 dibasic cyclopentane derivatives | |
| CN102030700B (en) | Benzamido carboxylic acid compound and method for making thereof and medicinal usage | |
| CN106543092A (en) | 1,5 2 aromatic radical, 1,2,4 triazole compound and its pharmaceutical applications | |
| CN105308040B (en) | 1,3- diamino cyclopentane formamide derivative | |
| CA2132841C (en) | Aminocyclohexylamides for antiarrhythmic and anaesthetic uses | |
| JP2006516281A (en) | Cardioprotective delta opioid receptor agonists and methods of use thereof | |
| KR20010083133A (en) | N,n-substituted cyclic amine derivatives | |
| KR20030090625A (en) | Amine derivatives modulating the funcitons of potassium channels, the preparation methods and uses thereof | |
| CN114181170A (en) | 10H-phenothiazine iron death inhibitor and preparation method and application thereof | |
| CN107468690A (en) | 4 o-alkylation tetramates acids compounds and preparation method and application | |
| CN102285962B (en) | Phenoxy alkyl piperazine compounds, preparation method thereof and medicinal use thereof | |
| KR20180103846A (en) | Application of substituted cinnamamide derivatives in the preparation of anxiolytics | |
| CN107353239A (en) | 4 o-alkylation tetramates acids compounds and preparation method thereof | |
| Koufaki et al. | Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores | |
| KR20060125862A (en) | Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency | |
| EP1783115B1 (en) | Arylamine ketones, their preparation methods, the pharmaceutical compositions containing them and their use | |
| CN102001971A (en) | N-(4-guanidyl butyl) syringoylagmatine derivatives and pharmaceutical applications thereof | |
| Zhou et al. | Design, synthesis and biological activity of a novel ethylenediamine derivatives as H1 receptor antagonists | |
| RU2309153C2 (en) | Enantiomerically pure opioid diarylmethyl piperazine and methods for uses thereof | |
| CN101503392A (en) | Aromatic aminomethane compounds, as well as preparation and medical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |